Altamira Therapeutics Stock Probability of Future Stock Price Finishing Over 0.64
| CYTO Stock | USD 0.46 0.03 6.12% |
Altamira |
Altamira Therapeutics Target Price Odds to finish over 0.64
The tendency of Altamira Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 0.64 or more in 90 days |
| 0.46 | 90 days | 0.64 | about 29.51 |
Based on a normal probability distribution, the odds of Altamira Therapeutics to move over $ 0.64 or more in 90 days from now is about 29.51 (This Altamira Therapeutics probability density function shows the probability of Altamira Stock to fall within a particular range of prices over 90 days) . Probability of Altamira Therapeutics price to stay between its current price of $ 0.46 and $ 0.64 at the end of the 90-day period is about 50.61 .
Given the investment horizon of 90 days Altamira Therapeutics has a beta of 0.12 suggesting as returns on the market go up, Altamira Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Altamira Therapeutics will be expected to be much smaller as well. Additionally Altamira Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Altamira Therapeutics Price Density |
| Price |
Predictive Modules for Altamira Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Altamira Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Altamira Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Altamira Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Altamira Therapeutics is not an exception. The market had few large corrections towards the Altamira Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Altamira Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Altamira Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.91 | |
β | Beta against Dow Jones | 0.12 | |
σ | Overall volatility | 0.13 | |
Ir | Information ratio | -0.19 |
Altamira Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Altamira Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Altamira Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Altamira Therapeutics generated a negative expected return over the last 90 days | |
| Altamira Therapeutics has high historical volatility and very poor performance | |
| Altamira Therapeutics has some characteristics of a very speculative penny stock | |
| Altamira Therapeutics currently holds 99.66 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Altamira Therapeutics has a current ratio of 0.75, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Altamira Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (3.87 M) with loss before overhead, payroll, taxes, and interest of (2.18 M). | |
| Altamira Therapeutics currently holds about 984.19 K in cash with (11.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from MacroaxisInsider: Acquisition by Mollica Joseph A of 138 shares of Altamira Therapeutics subject to Rule 16b-3 |
Altamira Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Altamira Stock often depends not only on the future outlook of the current and potential Altamira Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Altamira Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 491.3 K | |
| Cash And Short Term Investments | 617.4 K |
Altamira Therapeutics Technical Analysis
Altamira Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Altamira Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Altamira Therapeutics. In general, you should focus on analyzing Altamira Stock price patterns and their correlations with different microeconomic environments and drivers.
Altamira Therapeutics Predictive Forecast Models
Altamira Therapeutics' time-series forecasting models is one of many Altamira Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Altamira Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Altamira Therapeutics
Checking the ongoing alerts about Altamira Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Altamira Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Altamira Therapeutics generated a negative expected return over the last 90 days | |
| Altamira Therapeutics has high historical volatility and very poor performance | |
| Altamira Therapeutics has some characteristics of a very speculative penny stock | |
| Altamira Therapeutics currently holds 99.66 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Altamira Therapeutics has a current ratio of 0.75, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Altamira Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (3.87 M) with loss before overhead, payroll, taxes, and interest of (2.18 M). | |
| Altamira Therapeutics currently holds about 984.19 K in cash with (11.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from MacroaxisInsider: Acquisition by Mollica Joseph A of 138 shares of Altamira Therapeutics subject to Rule 16b-3 |
Check out Altamira Therapeutics Backtesting, Altamira Therapeutics Valuation, Altamira Therapeutics Correlation, Altamira Therapeutics Hype Analysis, Altamira Therapeutics Volatility, Altamira Therapeutics History as well as Altamira Therapeutics Performance. To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altamira Therapeutics. If investors know Altamira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altamira Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.82 | Revenue Per Share 0.917 | Quarterly Revenue Growth (0.64) | Return On Assets (0.57) | Return On Equity (3.69) |
The market value of Altamira Therapeutics is measured differently than its book value, which is the value of Altamira that is recorded on the company's balance sheet. Investors also form their own opinion of Altamira Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Altamira Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altamira Therapeutics' market value can be influenced by many factors that don't directly affect Altamira Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altamira Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Altamira Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altamira Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.